Author Archives: admin


Stem Cell Clinic > Articles by: admin

Tiziana Life Sciences Highlighted in Forbes Article

By Stell Cell Research

Article entitled "New T Cell Antibody Treatment Improves Outcomes For Covid Patients" reviews the company's first in class foralumab, a unique Intranasal monoclonal antibody designed to treat multiple sclerosis and a range of other neurodegenerative diseases Article entitled "New T Cell Antibody Treatment Improves Outcomes For Covid Patients" reviews the company's first in class foralumab, a unique Intranasal monoclonal antibody designed to treat multiple sclerosis and a range of other neurodegenerative diseases

More:
Tiziana Life Sciences Highlighted in Forbes Article

F2G Wins Investment Deal of the Year Bionow 2022 Award

By Stell Cell Research

MANCHESTER, United Kingdom, March 17, 2023 (GLOBE NEWSWIRE) -- F2G Ltd. today announced the company has been awarded a prestigious Bionow award in recognition of its contributions to the North England biotech industry and progress towards developing a new class of antifungals for treatment of rare fungal infections. F2G was awarded Investment Deal of the Year at the Bionow awards ceremony which was held at the iconic Concorde Conference Centre in Manchester, United Kingdom, on March 16, 2023.

Link:
F2G Wins Investment Deal of the Year Bionow 2022 Award

Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

By Stell Cell Research

SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth quarter and full year financial results for the period ending December 31, 2022.

Go here to read the rest:
Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

BridgeBio Pharma to Present Preliminary Findings on its Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (?DG) in Patients with Limb-girdle…

By Stell Cell Research

- BridgeBio will also share 15-month Phase 2 data and review the Phase 3 clinical trial design of BBP-418, a potential therapeutic for patients with LGMD2I, with initiation of its Phase 3 study expected in mid-2023

Go here to see the original:
BridgeBio Pharma to Present Preliminary Findings on its Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (?DG) in Patients with Limb-girdle...

Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting

By Stell Cell Research

REYKJAVIK, Iceland, March 17, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the presentation of two posters related to its clinical studies in support of biosimilarity and clinical comparability of Alvotech’s ATV04 (ustekinumab) and the reference product Stelara® at the 2023 American Academy of Dermatology (AAD) Annual Meeting, March 17-21 in New Orleans.

See original here:
Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Stell Cell Research

SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that on March 1, 2023, the Compensation Committee of Sutro’s Board of Directors (i) granted to Anne Borgman, M.D. 175,000 shares of Sutro Biopharma stock options and 150,000 restricted stock units (RSUs) of Sutro common stock in connection with her appointment as Sutro’s Chief Medical Officer and (ii) granted 10,000 RSUs of Sutro common stock to one other new employee. These grants were made as an inducement material to the employees’ acceptance of employment with Sutro and were approved by the Compensation Committee of Sutro’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).

Link:
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies…

By Global News Feed

COPENHAGEN, Denmark, March 17, 2023 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.

View post:
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies...

Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting

By Global News Feed

Fort Lee, NJ, March 17, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming presentations for NXP800 and NXP900 at the upcoming 2023 American Association for Cancer Research Meeting (2023 AACR), taking place from April 14th to April 19th in Orlando, Florida. Presentation details are below:

The rest is here:
Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting

→←